HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

BrainAurora Medical Technology / Equity Capital Markets

<ul>
<li>If the System or this treatment method is really effective and accepted by hospitals/doctors, under the coverage of medical insurance catalog already, why BrainAurora’s revenue scale is still so small?</li>
<li>CSRC questioned BrainAurora’s high selling expenses. Since either SG&amp;A or R&amp;D expenses already exceed revenue, BrainAurora would continue to suffer from losses. The Company hasn’t established a solid profit model.</li>
<li>BrainAurora completed a total of 7 rounds of financing, with a post investment valuation of RMB2.7 billion. However, it is difficult for BrainAurora to match this high valuation after IPO.</li>
</ul>


If the System or this treatment method is really effective and accepted by hospitals/doctors, under the coverage of medical insurance catalog already, why BrainAurora’s revenue scale is still so small?
CSRC questioned BrainAurora’s high selling expenses. Since either SG&amp;A or R&amp;D expenses already exceed revenue, BrainAurora would continue to suffer from losses. The Company hasn’t established a solid profit model.
BrainAurora completed a total of 7 rounds of financing, with a post investment valuation of RMB2.7 billion. However, it is difficult for BrainAurora to match this high valuation after IPO.


Pre-IPO BrainAurora Medical Technology (PHIP Updates) - Some Points Worth the Attention

<ul>
<li>DTx industry is still in the early stages of development. The establishment of a matching operation/service system is a very difficult task. There is a long distance from mature commercialization. </li>
<li>BrainAurora’s sales scale is small because its products haven’t received widespread recognition from medical system in China. Internationalization is challenging because it requires cross-border transfer of personal or scientific data.</li>
<li>BrainAurora’s business prospects is still unclear.As the attitude of capital market towards DTx has become more rational, investors have begun to doubt if this field could really bring good return.</li>
</ul>


DTx industry is still in the early stages of development. The establishment of a matching operation/service system is a very difficult task. There is a long distance from mature commercialization. 
BrainAurora’s sales scale is small because its products haven’t received widespread recognition from medical system in China. Internationalization is challenging because it requires cross-border transfer of personal or scientific data.
BrainAurora’s business prospects is still unclear.As the attitude of capital market towards DTx has become more rational, investors have begun to doubt if this field could really bring good return.


Pre-IPO BrainAurora Medical Technology - The Outlook Is Highly Uncertain

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

BrainAurora Medical Technology (BAMT HK)

Pre-IPO BrainAurora Medical Technology (PHIP Updates) - Some Points Worth the Attention

BrainAurora's small revenue scale indicates its products haven't been recognized as an effective treatment method by hospitals. Business prospects...

Xinyao (Criss) Wang

Pre-IPO BrainAurora Medical Technology - The Outlook Is Highly Uncertain

BrainAurora's products haven't received widespread recognition, leading to small revenue scale. Due to lack of commercialization path, Investors...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)